Amadeus trial: Tumor agnostic pre- and ontreatment biomarkers of response to nivolumab plus ipilimumab correlate with ontreatment tumoral T cell infiltration Meeting Abstract
| Authors: | Alayli, F.; Okrah, K.; Tsimberidou, A.; Drakaki, A.; Khalil, D.; Khan, S.; Hodi, S.; Oh, D.; Amouzgar, M.; Guatam, S.; Kageyama, R.; Pfeiffer, S.; Meier, S.; Cabanski, C.; Da Silva, D.; Kumar, D.; Santulli-Marotto, S.; Tetzlaff, M.; Foo, W. C.; Hollman, T.; Li, Y.; Adamow, M.; Wong, P.; Spasic, M.; Chen, R.; Bucktrout, S.; Fairchild, J.; Butterfield, L.; LaVallee, T.; Padron, L.; Salvador, L.; O'Donnell-Tormey, J.; Dugan, U.; Sharma, P. |
| Abstract Title: | Amadeus trial: Tumor agnostic pre- and ontreatment biomarkers of response to nivolumab plus ipilimumab correlate with ontreatment tumoral T cell infiltration |
| Meeting Title: | 37th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2022) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 10 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2022 Nov 8-12 |
| Meeting Location: | Boston, MA |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2022-11-01 |
| Start Page: | A614 |
| Language: | English |
| ACCESSION: | WOS:000919423400550 |
| DOI: | 10.1136/jitc-2022-SITC2022.0587 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 587 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work